GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Average Rating of "Moderate Buy" by Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received an average rating of "Moderate Buy" from the eleven analysts that are presently covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $6.55.

A number of equities analysts have recently commented on the stock. The Goldman Sachs Group decreased their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Truist Financial cut their price objective on shares of GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Wells Fargo & Company reduced their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Finally, UBS Group decreased their target price on GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th.

GoodRx Trading Up 0.5%

NASDAQ:GDRX opened at $3.97 on Wednesday. The firm has a fifty day simple moving average of $4.42 and a two-hundred day simple moving average of $4.63. GoodRx has a 12 month low of $3.68 and a 12 month high of $9.26. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -132.33, a PEG ratio of 2.46 and a beta of 1.24.

GoodRx (NASDAQ:GDRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.05. The firm had revenue of $202.97 million during the quarter, compared to analyst estimates of $202.25 million. GoodRx had a positive return on equity of 5.35% and a negative net margin of 2.05%. The company's revenue for the quarter was up 2.6% on a year-over-year basis. During the same period in the previous year, the company posted $0.08 EPS. Analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

Hedge Funds Weigh In On GoodRx

Institutional investors have recently added to or reduced their stakes in the company. IMC Chicago LLC acquired a new stake in shares of GoodRx during the 4th quarter valued at approximately $304,000. Geode Capital Management LLC raised its holdings in shares of GoodRx by 9.1% during the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock worth $4,986,000 after purchasing an additional 89,032 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of GoodRx in the 4th quarter valued at about $358,000. Barclays PLC raised its stake in GoodRx by 18.4% during the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock worth $772,000 after acquiring an additional 25,815 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in GoodRx by 358.7% in the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock valued at $169,000 after acquiring an additional 18,997 shares during the period. Institutional investors and hedge funds own 63.77% of the company's stock.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.